DSIP

Also known as: Delta Sleep-Inducing Peptide

Overview

DSIP promotes deep sleep, reduces pain, and helps manage withdrawal symptoms by regulating the sleep cycle and interacting with opioid systems. It also supports stress reduction, hormone regulation, and may offer neuroprotective benefits. DSIP is a synthetic nonapeptide discovered in 1977 for its ability to induce delta wave sleep. It is naturally found in the hypothalamus and influences the CNS by modulating the sleep-wake cycle, pain perception, and endocrine functions.

Benefits

- Improved sleep quality

- Reduced chronic pain

- Hormone regulation

- Anxiety reduction

- Withdrawal management

- Neuroprotection

Consider This Peptide If You Want To

- Improve sleep quality and regulate sleep-wake cycle (insomnia, disrupted sleep)

- Reduce stress and promote relaxation; support recovery from fatigue

Dosage & Administration

Dosage Guidelines

Recommended Dosage

• Amount:100 mcg

• Frequency:every 3 days

• Duration:n/a

• Rest Period:n/a

• Time of Day:evening

• Ingestion:subcutaneous

Administration Routes:SubcutaneousIntravenous

Research Findings on Dosage:

• Subcutaneous or Intravenous Injection:

◦ Commonly Reported Dosage: 100 mcg 3 hours before bedtime either daily, every 3 days, or weekly

◦ Duration: Reduce dosage to 50 mcg once per week once sleep stabilizes

Mechanism of Action

Mechanism of Action

How this peptide works in the body

Sleep Regulation:

DSIP binds to receptors in the hypothalamus and brainstem, influencing gamma-aminobutyric acid (GABA), serotonin, and noradrenaline signaling to regulate the sleep-wake cycle. It promotes delta wave sleep by reducing excitatory neurotransmission and increasing slow-wave sleep activity, which is essential for deep, restorative sleep and cognitive recovery.

Pain Relief:

DSIP modulates opioid-peptidergic systems by enhancing the release of endogenous opioid peptides, such as enkephalins and endorphins, which activate μ-opioid and δ-opioid receptors. This leads to reduced pain perception and increased pain tolerance, making DSIP beneficial for chronic and severe pain conditions.

Addiction and Withdrawal Management:

By interacting with opioid receptors and the hypothalamic-pituitary-adrenal (HPA) axis, DSIP reduces withdrawal symptoms and cravings associated with alcohol, opioids, and other addictive substances. It also stabilizes dopamine and serotonin levels, which helps mitigate anxiety, irritability, and stress-related relapse risks during withdrawal.

Endocrine Modulation:

DSIP influences hormone secretion by regulating the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol levels to mitigate stress-induced hormonal imbalances. It also stimulates luteinizing hormone (LH) and growth hormone-releasing hormone (GHRH), which support testosterone production, growth hormone release, and overall metabolic balance.

Consider Stacking With

- Any GHRP (Ipamorelin, Hexarelin)

- Any GHRH (CJC-1295, MOD-GRF-129, Tesamorelin)

- TA-1

- BPC-157

- TB-4

- Kisspeptin-10

- PEG-MGF

- Semax/Selank

- Cerebrolysin

Side Effects & Cautions

Common Side Effects

- Mild headaches

- Dizziness

- Fatigue

- Injection site redness/itching

Research & References

Research Highlights

Sleep Disorders (2021): Shown to improve sleep efficiency and reduce sleep latency in patients with chronic insomnia.

Pain Relief (2019): Significantly reduced chronic pain symptoms in clinical trials involving migraine and vasomotor headache patients.

Addiction Treatment (2018): Improved withdrawal symptoms in 97% of opiate addicts and 87% of alcoholics.

Cancer Prevention (2020): Reduced tumor occurrence in animal models, particularly in mammary carcinomas and leukemias.

References

"DSIP and Sleep Regulation Studies" – Journal of Sleep Research

"DSIP's Role in Chronic Pain Management" – Journal of Pain Medicine

"Neuroendocrine Effects of DSIP in Humans and Animals" – Endocrine Research Review

"DSIP as a Potential Treatment for Withdrawal Syndromes" – Addiction Science Journal

"Anti-Tumor Effects of DSIP in Rodent Models" – Oncology Research Reports